Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.
Along with greater life expectancy in patients with haemophilia has been an increase in associated haemophilia-related (arthropathy, osteoporosis, viral infections) and age-related (cardiovascular disease, renal disease, cancer and others) comorbidities, many of which are only just emerging as the population ages. At present, experience in managing these comorbidities is limited. As the demographic shift continues, haemophilia care centres can expect to encounter more patients with greater levels of complexity. In the absence of evidence-based information to guide the management of adult patients with haemophilia, it is important that the scientific position be reviewed on a regular basis. To this end, several topics relevant to the clinical management of adult patients with haemophilia were examined in a symposium entitled Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies held on 11 February 2015 in Helsinki, Finland, in conjunction with the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders. This article is a summary of that event.
Clinical Coagulation Research Unit, Skåne University Hospital, Malmö, Sweden.
Erik
E
Berntorp
Van Creveldkliniek, Department of Benign Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Evelien
E
Mauser-Bunschoten
La Paz University Hospital, Coagulopathy Unit, Haematology Service, Madrid, Spain.
Víctor
V
Jiménez-Yuste
Grifols, Research Triangle Park, NC, USA.
Jeffrey B
JB
Spears
D000328:Adult; D015897:Comorbidity; D017281:Cost of Illness; D006467:Hemophilia A / Q000191:economics / Q000628:therapy*; D006801:Humans; D012307:Risk Factors
comorbidities; haemophilia; inhibitors